Wallbach, Manuel

[["dc.bibliographiccitation.firstpage","257"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Hypertension"],["dc.bibliographiccitation.lastpage","264"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Heusser, Karsten"],["dc.contributor.author","Thöne, Arvo"],["dc.contributor.author","Lipp, Axel"],["dc.contributor.author","Menne, Jan"],["dc.contributor.author","Beige, Joachim"],["dc.contributor.author","Reuter, Hannes"],["dc.contributor.author","Hoffmann, Fabian"],["dc.contributor.author","Halbach, Marcel"],["dc.contributor.author","Eckert, Siegfried"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Joyner, Michael J."],["dc.contributor.author","Paton, Julian F.R."],["dc.contributor.author","Diedrich, André"],["dc.contributor.author","Haller, Hermann"],["dc.contributor.author","Jordan, Jens"],["dc.contributor.author","Tank, Jens"],["dc.date.accessioned","2020-12-10T18:38:04Z"],["dc.date.available","2020-12-10T18:38:04Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1161/HYPERTENSIONAHA.119.13925"],["dc.identifier.eissn","1524-4563"],["dc.identifier.issn","0194-911X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77177"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Efficacy of Electrical Baroreflex Activation Is Independent of Peripheral Chemoreceptor Modulation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","718"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","JAMA Ophthalmology"],["dc.bibliographiccitation.lastpage","720"],["dc.bibliographiccitation.volume","133"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Patschan, Daniel"],["dc.contributor.author","Desel, Herbert"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Callizo, Josep"],["dc.date.accessioned","2018-11-07T09:56:31Z"],["dc.date.available","2018-11-07T09:56:31Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1001/jamaophthalmol.2015.191"],["dc.identifier.isi","000356044400026"],["dc.identifier.pmid","25742635"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36970"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Medical Assoc"],["dc.relation.issn","2168-6173"],["dc.relation.issn","2168-6165"],["dc.title","Closantel Poisoning Treated With Plasma Exchange"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","829"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Acta Diabetologica"],["dc.bibliographiccitation.lastpage","835"],["dc.bibliographiccitation.volume","52"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Lehnig, Luca-Yves"],["dc.contributor.author","Helms, Hans-Joachim"],["dc.contributor.author","Schroer, Charlotte"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Wachter, R. Rolf"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T09:51:13Z"],["dc.date.available","2018-11-07T09:51:13Z"],["dc.date.issued","2015"],["dc.description.abstract","Aims Sympathetic overactivity is one critical factor associated with the development of arterial hypertension, impaired insulin secretion and resistance. Some antihypertensives exert beneficial effects on glucose metabolism, whereas others lead to an impairment of metabolic state with consecutive weight gain. In resistant hypertension, baroreflex activation therapy (BAT) reduces arterial blood pressure (BP) by inhibition of the sympathetic nervous system. The objective of this study was to evaluate whether BAT influences metabolic state in patients with resistant hypertension. Methods Thirty patients with resistant hypertension (10 with known diabetes mellitus) were prospectively included into this study. Blood pressure, BMI, weight, fasting glucose, insulin, C-peptide, hemoglobin A1c, HOMA-IR, HOMA-beta, ISQuickI, and glucose levels during oral glucose tolerance test were measured at baseline and 6 months after BAT activation. Results Fasting glucose was significantly reduced after 6 months of BAT, whereas mean 2-h glucose levels during oral glucose tolerance test, fasting insulin levels, C-peptide levels, hemoglobin A1c, HOMA-IR, HOMA-beta, ISQuickI, weight, and BMI remained unchanged. Conclusion Despite improvement in fasting glucose, BAT exerts neither sustained additional beneficial effects nor an impairment of metabolic state. Thus, chronic BAT might be an effective interventional method to reduce BP without metabolic disadvantages."],["dc.description.sponsorship","CVRx"],["dc.identifier.doi","10.1007/s00592-014-0679-7"],["dc.identifier.isi","000361346500002"],["dc.identifier.pmid","25539879"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35870"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-5233"],["dc.relation.issn","0940-5429"],["dc.title","Long-term effects of baroreflex activation therapy on glucose metabolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","578"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Der Internist"],["dc.bibliographiccitation.lastpage","586"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Wallbach, M."],["dc.contributor.author","Tampe, B."],["dc.contributor.author","Dihazi, H."],["dc.contributor.author","Koziolek, M. J."],["dc.date.accessioned","2020-12-10T14:08:25Z"],["dc.date.available","2020-12-10T14:08:25Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00108-019-0602-y"],["dc.identifier.eissn","1432-1289"],["dc.identifier.issn","0020-9554"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70458"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Akute Nierenschädigung: von Kreatinin zu KIM‑1?"],["dc.title.alternative","Acute kidney injury: from creatinine to KIM‑1?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Artificial Organs"],["dc.contributor.author","Rademacher, Jan-Gerd"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Koziolek, Michael J."],["dc.contributor.author","Zeisberg, Michael"],["dc.contributor.author","Wallbach, Manuel"],["dc.date.accessioned","2021-04-14T08:30:38Z"],["dc.date.available","2021-04-14T08:30:38Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s10047-020-01244-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83319"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1619-0904"],["dc.relation.issn","1434-7229"],["dc.title","Cytokine adsorption therapy in lymphoma-associated hemophagocytic lymphohistiocytosis and allogeneic stem cell transplantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1287"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","1296"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Lipphardt, Mark"],["dc.contributor.author","Koziolek, Michael J."],["dc.contributor.author","Lehnig, Luca-Yves"],["dc.contributor.author","Schäfer, Ann-Kathrin"],["dc.contributor.author","Müller, Gerhard A."],["dc.contributor.author","Lüders, Stephan"],["dc.contributor.author","Wallbach, Manuel"],["dc.date.accessioned","2020-12-10T14:10:22Z"],["dc.date.available","2020-12-10T14:10:22Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00392-019-01464-4"],["dc.identifier.eissn","1861-0692"],["dc.identifier.issn","1861-0684"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70741"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Effect of baroreflex activation therapy on renal sodium excretion in patients with resistant hypertension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","747"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Evaluation in Clinical Practice"],["dc.bibliographiccitation.lastpage","754"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Kröplin, Juliane"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Minguet, Joan"],["dc.contributor.author","Smith, Katherine Helen"],["dc.contributor.author","Lüders, Stephan"],["dc.contributor.author","Schrader, Joachim"],["dc.contributor.author","Patschan, Susan"],["dc.contributor.author","Gross, Oliver"],["dc.contributor.author","Deutsch, Cornelia"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Müller, Gerhard Anton"],["dc.contributor.author","Koziolek, Michael"],["dc.date.accessioned","2020-12-10T18:28:59Z"],["dc.date.available","2020-12-10T18:28:59Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/jep.12709"],["dc.identifier.issn","1356-1294"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76484"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Management of cardiovascular risk factors in patients with ANCA-associated vasculitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3051"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Lipphardt, Mark"],["dc.contributor.author","Dihazi, Hassan"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Schäfer, Ann-Kathrin"],["dc.contributor.author","Amlaz, Saskia I."],["dc.contributor.author","Ratliff, Brian B."],["dc.contributor.author","Koziolek, Michael J."],["dc.contributor.author","Wallbach, Manuel"],["dc.date.accessioned","2021-04-14T08:32:33Z"],["dc.date.available","2021-04-14T08:32:33Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/jcm9093051"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17590"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83944"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","235"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Clinical Apheresis"],["dc.bibliographiccitation.lastpage","242"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Strauchmann, Julia"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Bramlage, Carsten"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T09:34:08Z"],["dc.date.available","2018-11-07T09:34:08Z"],["dc.date.issued","2014"],["dc.description.abstract","Lipoprotein apheresis (LA) is believed to exert anti-atherosclerotic effects beyond LDL-cholesterol reduction. We investigated 22 patients undergoing regular LA on a weekly basis (group A) before (AP) and after LA procedure (EP), 15 healthy individuals (group B), and 22 hyperlipoproteinemic patients with concomitant cardiovascular end organ damage treated without LA therapy (group C). Biomarkers of endothelial inflammation (hsCRP), plaque destabilization, and rupture (sVCAM, MMP-9, PAPP-A, ADMA) were quantified. Intergroup comparison revealed a statistically significant lower MMP-9 level in group A (AP and EP) compared with group C (P<0.01), whereas PAPP-A levels were lower in group B compared with group A and C (P=0.04). EP ADMA-levels and EP sVCAM levels in group A were statistically lower compared with group B and C. AP and EP values comparison revealed a significant reduction for hsCRP (mean 41.0 +/- 16.7%, P<0.01), sVCAM (mean 69.6 +/- 14.0%, P<0.01), PAPP-A (mean 88.7 +/- 20.4%, P<0.01), ADMA (mean 69.7 +/- 18.4% P<0.01). In conclusion, we observed a transient decrease in the plasma concentrations of several biomarkers expressed during plaque destabilization and elevated cardiovascular risk after a single LA treatment. J. Clin. Apheresis 29:235-242, 2014. (c) 2013 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/jca.21311"],["dc.identifier.isi","000343831500001"],["dc.identifier.pmid","24281903"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32112"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1098-1101"],["dc.relation.issn","0733-2459"],["dc.title","Lipoprotein Apheresis Reduces Biomarkers of Plaque Destabilization and Cardiovascular Risk"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2939"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Clinical Rheumatology"],["dc.bibliographiccitation.lastpage","2946"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Froelich, Britta"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Minguet, Joan"],["dc.contributor.author","Grupp, Clemens"],["dc.contributor.author","Deutsch, Cornelia"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Mueller, Gerhard Anton"],["dc.date.accessioned","2018-11-07T10:05:16Z"],["dc.date.available","2018-11-07T10:05:16Z"],["dc.date.issued","2016"],["dc.description.abstract","In patients with rheumatic diseases, reliable markers for determining disease activity are scarce. One potential parameter is the level of immunoglobulin free light chains (FLCs), which is known to be elevated in the blood of patients with certain rheumatic diseases. Few studies have quantified FLCs in urine, a convenient source of test sample, in patients with different rheumatic diseases. We carried out a retrospective analysis of patients with rheumatic disease attending the University hospital of Goettingen, Germany. Subjects were included if they had urine levels of both kappa and lambda FLCs available and did not have myeloma. Data regarding systemic inflammation and kidney function were recorded, and FLC levels were correlated with inflammatory markers. Of the 382 patients with rheumatic disease, 40.1 % had chronic polyarthritis, 21.2 % connective tissue disease, 18.6 % spondyloarthritis and 15.7 % vasculitis. Elevated levels of kappa FLCs were found for 84 % of patients and elevated lambda for 52.7 %. For the patients with rheumatoid arthritis, FLCs correlated with C-reactive protein (kappa, r = 0.368, p < 0.001; lambda, r = 0.398, p < 0.001) and erythrocyte sedimentation rate (kappa, r = 0.692, p < 0.001; lambda, r = 0.612, p < 0.001). Patients being treated with rituximab displayed FLC levels similar to those of the reference group. There were clear elevations in both kappa and lambda FLCs in patients with rheumatic disease, but not in kappa/lambda ratio. The correlation between FLCs and inflammatory markers in patients with rheumatoid arthritis demonstrates their potential for predicting disease activity."],["dc.identifier.doi","10.1007/s10067-016-3437-0"],["dc.identifier.isi","000388826200010"],["dc.identifier.pmid","27734231"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38865"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","London"],["dc.relation.issn","1434-9949"],["dc.relation.issn","0770-3198"],["dc.title","The significance and predictive value of free light chains in the urine of patients with chronic inflammatory rheumatic disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]